Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

End of Methotrexate for CNS Prophylaxis in Diffuse Large B-Cell Lymphoma.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026
Same author

Development and Validation of a Novel Conditional Event-Free Survival Tool in Diffuse Large B-Cell Lymphoma.

American journal of hematology·2026
Same author

Diagnosis-to-treatment interval is associated with outcomes in follicular lymphoma treated with immunochemotherapy.

Blood·2026
Same author

Brentuximab vedotin and dose attenuated chemoimmunotherapy for patients 75 years and older with diffuse large B-cell lymphoma with analysis of outcomes by frailty.

Journal of geriatric oncology·2026
Same author

Treatment of Follicular Lymphoma With CHOP and Anti-CD20 Therapy: 15-Year Follow-Up of the SWOG S0016 Trial.

JAMA oncology·2026
Same author

Repression of miR-29 via MYC leads to increased CD40 signaling in transformed follicular lymphoma.

Leukemia·2026

Related Experiment Video

Updated: Apr 15, 2026

Enhancing Tumor Content through Tumor Macrodissection
10:04

Enhancing Tumor Content through Tumor Macrodissection

Published on: February 12, 2022

12.9K

Double hit diffuse large B-cell lymphomas: diagnostic and therapeutic challenges.

Jonathan W Friedberg1

  • 1Samuel Durand Professor of Medicine, University of Rochester, Rochester, NY 14642, USA. jonathan_friedberg@urmc.rochester.edu.

Chinese Clinical Oncology
|April 6, 2015
PubMed
Summary

Diffuse large B-cell lymphoma (DLBCL) with MYC and BCL-2 rearrangements, known as double-hit DLBCL, presents a poor prognosis. Emerging data suggests dose-adjusted EPOCH-R chemotherapy may benefit these high-risk patients.

Keywords:
Bcl-2Large cell lymphomaMyctreatment

More Related Videos

VDJ-Seq: Deep Sequencing Analysis of Rearranged Immunoglobulin Heavy Chain Gene to Reveal Clonal Evolution Patterns of B Cell Lymphoma
15:07

VDJ-Seq: Deep Sequencing Analysis of Rearranged Immunoglobulin Heavy Chain Gene to Reveal Clonal Evolution Patterns of B Cell Lymphoma

Published on: December 28, 2015

27.4K
Multiplexed Fluorescent Immunohistochemical Staining, Imaging, and Analysis in Histological Samples of Lymphoma
07:52

Multiplexed Fluorescent Immunohistochemical Staining, Imaging, and Analysis in Histological Samples of Lymphoma

Published on: January 9, 2019

20.7K

Related Experiment Videos

Last Updated: Apr 15, 2026

Enhancing Tumor Content through Tumor Macrodissection
10:04

Enhancing Tumor Content through Tumor Macrodissection

Published on: February 12, 2022

12.9K
VDJ-Seq: Deep Sequencing Analysis of Rearranged Immunoglobulin Heavy Chain Gene to Reveal Clonal Evolution Patterns of B Cell Lymphoma
15:07

VDJ-Seq: Deep Sequencing Analysis of Rearranged Immunoglobulin Heavy Chain Gene to Reveal Clonal Evolution Patterns of B Cell Lymphoma

Published on: December 28, 2015

27.4K
Multiplexed Fluorescent Immunohistochemical Staining, Imaging, and Analysis in Histological Samples of Lymphoma
07:52

Multiplexed Fluorescent Immunohistochemical Staining, Imaging, and Analysis in Histological Samples of Lymphoma

Published on: January 9, 2019

20.7K

Area of Science:

  • Hematology
  • Oncology
  • Genetics

Background:

  • Diffuse large B-cell lymphoma (DLBCL) is a curable hematologic malignancy, yet over 30% of advanced-stage patients face refractory disease or progression.
  • MYC oncogene rearrangement occurs in ~10% of DLBCL cases, significantly worsening prognosis, especially with concurrent BCL-2 rearrangement (double-hit DLBCL).
  • Increased MYC expression, detected by immunohistochemistry in up to 30% of DLBCLs, and positive BCL-2 expression also indicate a poor prognosis.

Purpose of the Study:

  • To review the prognostic implications of MYC and BCL-2 alterations in DLBCL.
  • To explore current treatment strategies and emerging therapeutic options for double-hit DLBCL.
  • To survey novel agents for potential integration into chemotherapy regimens for high-risk DLBCL.

Main Methods:

  • Literature review of studies investigating MYC and BCL-2 rearrangements and expression in DLBCL.
  • Analysis of emerging datasets on treatment outcomes for double-hit DLBCL.
  • Survey of novel therapeutic agents relevant to DLBCL treatment.

Main Results:

  • MYC rearrangement, particularly with BCL-2 rearrangement (double-hit DLBCL), is associated with a very poor prognosis.
  • Increased MYC and/or BCL-2 expression via immunohistochemistry also correlates with unfavorable outcomes.
  • Emerging data suggests dose-adjusted EPOCH-R chemotherapy may be a viable treatment option for double-hit DLBCL.

Conclusions:

  • Double-hit DLBCL represents a high-risk subset requiring tailored therapeutic approaches.
  • Dose-adjusted EPOCH-R chemotherapy shows promise for this patient group.
  • Further research into novel agents is crucial for optimizing treatment strategies in high-risk DLBCL.